Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jadenu versus Exjade for liver and cardiac iron overload in beta-thalassemia
IRCT20210830052346N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of deferasirox in beta thalassemia, beta-thalassemia intermedia and iron overload (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Cardiac iron load, Liver iron load and 4 more. Started Nov 2021; status: completed.
02
Drugs
deferasirox
03
Conditions
beta thalassemiabeta-thalassemia intermediairon overload
Beyond the preview
Go deeper on IRCT20210830052346N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210830052346N1.